Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD/Safety of Gefurulimab in Healthy Chinese Adults
NCT06677138Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gefurulimab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum Observed Serum Concentration at Day 92 and Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity at Day 92. Started Oct 2024; status: completed.
02
Drugs
gefurulimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06677138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677138.